Urothelial Carcinoma of the Renal Pelvis and Ureter

Not yet reviewed

This information is AI generated and has not yet been reviewed by a specialist physician. AI can make mistakes.

Disease overview

Rare cancer from the transitional layer of the bladder. Presents with hematuria, commonly among people with risk factors such as cigarette smoking, genetics, painkiller abuse, excessive coffee drinking, and use of cyclophosphamide. Thought to be caused by a loss of a tumor suppressor gene like p53, p19, or p16.

Common symptoms

Hematurialower back painpain with urinationunexplained weight loss.

When to suspect

  • Recommendation 1

    Urine and blood tests for kidney, liver, and bladder function. Assess for infection and obtain CT urogram or uroscopy to visualize cancerous mass.

How to test

  • Recommendation 1

    Urine and blood tests for kidney, liver, and bladder function. Assess for infection and obtain CT urogram or uroscopy to visualize cancerous mass.

ZebraMD is partnering with Ambry Genetics for clinical-grade whole genome testing for rare diseases. Ambry accepts insurance. If you don’t have a physician to order this test, join our referral list and our team will reach out.

Treatment

  • Recommendation 1

    Radical nephroureterectomy is the most common form of treatment. Chemotherapy may be used for higher grade tumor. Jelmyto is an FDA-approved treatment for low-grade urether transitional cell cancers.

Primary care

  • Recommendation 1

    Staging and biopsy of cancer will determine need for chemotherapy and long-term management.

Further support

  • Recommendation 1

    Urologists and oncologist referral for surgery, chemotherapy, and long-term monitoring of recurrence. Referral to Medical Genetics Department, if available. Initial virtual care is also available through organizations like TeleRare Health.

Clinical trials

Clinical Trials

Sources

No data available

Interested in learning more about Urothelial Carcinoma of the Renal Pelvis and Ureter?

Follow to receive regular updates to the latest research development on this disease via email newsletter.